{"id":177711,"date":"2021-06-25T09:59:58","date_gmt":"2021-06-25T13:59:58","guid":{"rendered":"https:\/\/z3news.com\/w\/?p=177711"},"modified":"2021-07-26T15:42:44","modified_gmt":"2021-07-26T19:42:44","slug":"cdc-fda-prepare-mass-distribution-of-a-merck-sanofi-six-in-one-vaccine-for-kids-turning-blind-eye-to-safety-signals","status":"publish","type":"post","link":"https:\/\/z3news.com\/w\/cdc-fda-prepare-mass-distribution-of-a-merck-sanofi-six-in-one-vaccine-for-kids-turning-blind-eye-to-safety-signals\/","title":{"rendered":"CDC, FDA Prepare Mass Distribution of a Merck\/Sanofi Six-in-One Vaccine for Kids, Turning Blind Eye to Safety Signals"},"content":{"rendered":"

Since the mid-1980s, the number of childhood shots on the Centers for Disease Control and Prevention (CDC) vaccine schedule has more than quadrupled<\/a>. When parents express reluctance about turning their little ones into perpetual pin cushions, drug makers and doctors have a ready answer \u2014 combination vaccines<\/a> that \u201csimplify\u201d the schedule by decreasing the number of injections administered.<\/p>\n

This month marks the U.S. launch of the Merck\/Sanofi joint-venture vaccine, Vaxelis, a six-in-one (hexavalent) combination vaccine that contains diphtheria, tetanus and acellular pertussis (DTaP) components as well as components said to protect against polio, Haemophilus influenzae type b<\/a> (Hib) and hepatitis B.<\/p>\n

Public health officials optimistically believe that bundling all of these components into one shot will help close noncompliance<\/a> loopholes and increase the likelihood that children will complete \u201call recommended vaccinations.\u201d<\/p>\n

Though Vaxelis<\/a> is the nation\u2019s first<\/a> hexavalent injection, it joins other four- or five-in-one vaccines already on the CDC schedule. The U.S. Food and Drug Administration (FDA) approved<\/a> Vaxelis in late 2018 \u2014 as a three-dose series for 2-, 4- and 6-month-old infants \u2014 but it is only now, two-and-a-half years later, that the shot is being readied for widespread distribution.<\/p>\n

Warning signs were ignored<\/strong><\/p>\n

There are numerous warning signs<\/a> that potent all-in-one vaccines are too much for immature immune systems to handle. Concerning safety signals have emerged not just for hexavalent<\/a> but also pentavalent<\/a> (five-in-one) vaccines.<\/p>\n

In Europe, where infants have been given hexavalent vaccines for some years (including Vaxelis since 2016<\/a>), the formulations have produced many troubling reports of sudden infant death<\/a>.<\/p>\n

Absurdly, none of the clinical studies assessing Vaxelis safety and efficacy conducted fair comparisons against an inert placebo. Instead, in the two U.S. clinical trials<\/a> for Vaxelis, not only did investigators compare infants receiving Vaxelis to babies who received Sanofi\u2019s five-in-one Pentacel<\/a> \u2014 but babies in both groups also received rotavirus and pneumococcal vaccines at the same time!<\/p>\n

In this context, the CDC\u2019s sales pitch to the public \u2014 and its claims that side effects are \u201cusually mild\u201d \u2014 cannot be considered credible.<\/p>\n

Here are some of the other facts missing from the CDC\u2019s communications:<\/p>\n